The advent of CAR T‐cell therapy has seen significant improvements in survival and is a potential cure for patients with advanced haematological malignancies
Cancer immunotherapy is a burgeoning field which, in the last decade, has produced unprecedented improvements in outcomes across a variety of advanced malignancies. The eventual translation of decades of research into clinically available immunotherapies stems from the expanded knowledge of the role that the immune system plays in preventing tumour initiation and progression as well as the mechanisms by which tumours learn to evade this immune surveillance.1
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.